(Q37071204)

18 August 2017

1 reference

title

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma (English)

1 reference

18 August 2017

Guru Sonpavde

1

1 reference

18 August 2017

Thomas E Hutson

series ordinal

2

1 reference

18 August 2017

Cora N Sternberg

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Investigational Drugs

18 August 2017

1 reference

18 August 2017

17

1 reference

18 August 2017

253-261

1 reference

18 August 2017

2

1 reference

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

18 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Signal-transduction inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

Molecular and cellular biomarkers for angiogenesis in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.253

10.1517/13543784.17.2.253

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference